Key takeaways
- FLGR-242 is sold as a lab-made, shortened form of follistatin that binds myostatin and activin, two signals that hold back muscle growth.
- We found no published studies of FLGR-242 itself and no registered clinical trials. It is not FDA-approved.
- Blocking this pathway clearly builds muscle in animals, and a related antibody (bimagrumab) has shown lean-mass benefits in human trials.
- None of that research tested FLGR-242, so its effects, safety and dose in people are unknown.
Interest in myostatin blockers has grown with GLP-1 weight-loss drugs. When people lose a lot of weight, some of it is muscle, and drug companies are testing ways to protect that muscle. FLGR-242 is one of several research-only products marketed around that idea.
This post separates what has been published about the pathway from what is known about this specific product. The short version: the pathway is real and well studied, but FLGR-242 itself has almost no published record.
What FLGR-242 is said to be
FLGR-242 is described as a recombinant, truncated form of follistatin, a protein the body already makes. It is designed to bind myostatin and activin. That stops them from activating activin type II receptors, which reduces SMAD2/3 signaling, a chain of messages that tells muscle to stop growing.
It is not FDA-approved and is sold only as a research chemical. The FDA has not evaluated it for safety or effectiveness. On our scale it scores 1 out of 5 for evidence: there are no published human, animal or lab studies of FLGR-242 itself.
Vendors claim a half-life of about 2–3 weeks. We could not find any published data on how the body handles this compound, so treat that figure as a sales claim rather than a measured fact.
What we searched for, and what we found
We searched PubMed for "FLGR-242" and "FLGR242" and got zero results 1. A search of ClinicalTrials.gov for FLGR-242 also returned no registered studies 2. We found no company press release, patent filing or grant that clearly ties to this product name.
That means anything said about FLGR-242's effects in people comes from borrowed research on related molecules, not from tests of the product in the vial.
Why scientists care about myostatin
Myostatin was discovered in 1997. Mice bred without the myostatin gene had individual muscles that weighed 2–3 times more than normal mice 3. The muscle gain came from both more muscle cells and larger ones.
In 2001 the same lab showed that myostatin acts through the activin type II receptors, and that follistatin can block that binding 4. Mice engineered to make extra follistatin in their muscles grew dramatically larger muscles, similar to mice with no myostatin at all 4.
Follistatin has also been tested by gene therapy, where a virus delivers the gene into muscle. In monkeys, injecting a follistatin gene into the thigh muscle produced lasting gains in muscle size and strength without obvious organ damage 5. A small human trial in six men with Becker muscular dystrophy used the same approach. Four of the six walked further on a 6-minute walk test, and no adverse effects were reported 6.
Gene therapy is a very different thing from injecting a protein. The body makes follistatin continuously after gene delivery, while an injected protein is cleared over time. Results from gene therapy can't be assumed to carry over.
A follistatin-based drug that was tested, then dropped
The closest human data comes from ACE-083, a recombinant fusion protein made from modified human follistatin and developed by Acceleron. It was injected directly into single muscles in adults with facioscapulohumeral muscular dystrophy (FSHD) 7.
Muscle volume went up. Compared with placebo, total muscle volume rose by 16.4% in the biceps group and 9.5% in the shin-muscle group 7. But bigger muscles did not lead to consistent improvements in function, such as walking or arm use, or in how patients said they felt. The FSHD program was discontinued 7.
That's a useful warning. More muscle on a scan doesn't automatically mean more strength or better daily function.
Myostatin pathway drugs and GLP-1 weight loss
The strongest human evidence for this pathway comes from bimagrumab, an antibody that blocks the activin type II receptors directly. It is not follistatin, and it is not FLGR-242, but it targets the same signaling system.
In a 48-week trial in 75 adults with type 2 diabetes and obesity, bimagrumab cut fat mass by 20.5% and increased lean mass by 3.6%, compared with almost no change on placebo 8.
The BELIEVE phase 2 trial then tested bimagrumab with semaglutide in 507 adults with obesity 9. At 48 weeks, people on semaglutide 2.4 mg alone lost 3.9 kg of lean mass, while those on the high-dose combination lost 1.3 kg 9. In the combination group, 92.3% of the weight lost was fat, compared with 71.1% on semaglutide alone 9. Muscle spasms, diarrhea and acne were common side effects of bimagrumab 9.
These are company-sponsored results from a drug given by IV infusion under trial conditions. They show the pathway can change body composition in people. They say nothing about whether a research vial of FLGR-242 does the same, or is safe.
What remains unknown about FLGR-242
- Identity and purity. There is no published structure or independent analysis tying the product to a defined molecule.
- Whether it works in people. No human, animal or lab study of FLGR-242 has been published.
- Safety. Follistatin also binds activin, which has roles outside muscle. Researchers in the monkey study chose a specific follistatin form partly to limit effects on non-muscle tissue 5. Whether FLGR-242 does the same is unknown.
- How long it lasts. The 2–3 week half-life is a vendor claim with no published data behind it.
The bottom line
Blocking myostatin and activin is a serious area of research, with strong animal data and real human trials of related drugs like bimagrumab. FLGR-242 itself has no published studies and no registered trials, so its benefits and risks in people are simply unknown. The research on related drugs can't stand in for evidence about this product.
This is educational information, not medical advice.
Sources
- PubMed search for "FLGR-242" (0 results, searched Oct. 27, 2026) — National Library of Medicine. https://pubmed.ncbi.nlm.nih.gov/?term=FLGR-242
- ClinicalTrials.gov search for "FLGR-242" (no studies found, searched Oct. 27, 2026) — National Library of Medicine. https://clinicaltrials.gov/search?term=FLGR-242
- Regulation of skeletal muscle mass in mice by a new TGF-beta superfamily member — Nature, 1997. https://pubmed.ncbi.nlm.nih.gov/9139826/
- Regulation of myostatin activity and muscle growth — PNAS, 2001. https://pubmed.ncbi.nlm.nih.gov/11459935/
- Follistatin gene delivery enhances muscle growth and strength in nonhuman primates — Science Translational Medicine, 2009. https://pubmed.ncbi.nlm.nih.gov/20368179/
- A phase 1/2a follistatin gene therapy trial for Becker muscular dystrophy — Molecular Therapy, 2015. https://pubmed.ncbi.nlm.nih.gov/25322757/
- Randomized phase 2 study of ACE-083, a muscle-promoting agent, in facioscapulohumeral muscular dystrophy — Muscle & Nerve, 2022. https://pubmed.ncbi.nlm.nih.gov/35428982/
- Effect of bimagrumab vs placebo on body fat mass among adults with type 2 diabetes and obesity: a phase 2 randomized clinical trial — JAMA Network Open, 2021. https://pubmed.ncbi.nlm.nih.gov/33439265/
- Bimagrumab plus semaglutide alone or in combination for the treatment of obesity: a randomized phase 2 trial (BELIEVE) — Nature Medicine, 2026. https://pubmed.ncbi.nlm.nih.gov/41772149/
